Bleakley Financial Group LLC Has $25.52 Million Position in Eli Lilly and Company $LLY

Key Points

• Bleakley Financial Group LLC increased its position in Eli Lilly and Company by 18.6% during the second quarter, holding shares valued at approximately $25.52 million.
• Several analysts have lowered price targets for Eli Lilly, with UBS Group setting a new target at $895.00 and Cantor Fitzgerald at $925.00, while maintaining a generally positive sentiment with the consensus rating at "Moderate Buy".
• CEO David A. Ricks and Director Gabrielle Sulzberger both made recent insider purchases of Eli Lilly shares, indicating confidence in the company's market performance amidst fluctuations.

Bleakley Financial Group LLC lifted its position in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 18.6% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 32,739 shares of the company's stock after acquiring an additional 5,130 shares during the period. Bleakley Financial Group LLC's holdings in Eli Lilly and Company were worth $25,521,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also added to or reduced their stakes in the company. WestEnd Advisors LLC increased its stake in shares of Eli Lilly and Company by 210.0% in the 1st quarter. WestEnd Advisors LLC now owns 31 shares of the company's stock valued at $26,000 after purchasing an additional 21 shares during the last quarter. Wealth Preservation Advisors LLC acquired a new stake in Eli Lilly and Company in the first quarter valued at about $27,000. Blume Capital Management Inc. grew its position in Eli Lilly and Company by 46.7% in the second quarter. Blume Capital Management Inc. now owns 44 shares of the company's stock valued at $34,000 after acquiring an additional 14 shares during the last quarter. Citizens National Bank Trust Department raised its stake in Eli Lilly and Company by 180.0% during the first quarter. Citizens National Bank Trust Department now owns 42 shares of the company's stock worth $35,000 after acquiring an additional 27 shares in the last quarter. Finally, IMG Wealth Management Inc. bought a new position in shares of Eli Lilly and Company in the second quarter worth about $35,000. 82.53% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on LLY shares. Leerink Partnrs lowered shares of Eli Lilly and Company from a "strong-buy" rating to a "hold" rating in a report on Thursday, August 7th. Cantor Fitzgerald set a $925.00 target price on shares of Eli Lilly and Company and gave the company an "overweight" rating in a research report on Thursday, October 9th. UBS Group lowered their price target on shares of Eli Lilly and Company from $1,050.00 to $895.00 and set a "buy" rating for the company in a report on Friday, August 8th. Morgan Stanley dropped their price target on Eli Lilly and Company from $1,028.00 to $1,023.00 and set an "overweight" rating for the company in a research note on Friday, October 3rd. Finally, Guggenheim reissued a "buy" rating and set a $948.00 price objective on shares of Eli Lilly and Company in a report on Thursday, October 16th. One research analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating and nine have assigned a Hold rating to the company. Based on data from MarketBeat, Eli Lilly and Company currently has a consensus rating of "Moderate Buy" and a consensus target price of $938.61.

Insiders Place Their Bets

In related news, CEO David A. Ricks acquired 1,632 shares of the stock in a transaction dated Tuesday, August 12th. The stock was purchased at an average cost of $644.77 per share, with a total value of $1,052,264.64. Following the completion of the purchase, the chief executive officer directly owned 546,601 shares in the company, valued at $352,431,926.77. This trade represents a 0.30% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Gabrielle Sulzberger bought 117 shares of the business's stock in a transaction that occurred on Tuesday, August 12th. The shares were bought at an average cost of $641.18 per share, for a total transaction of $75,018.06. Following the transaction, the director owned 2,703 shares of the company's stock, valued at $1,733,109.54. The trade was a 4.52% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have purchased 4,514 shares of company stock worth $2,894,841 in the last 90 days. Company insiders own 0.13% of the company's stock.

Eli Lilly and Company Stock Performance

Shares of LLY stock opened at $812.33 on Thursday. The firm has a market capitalization of $768.84 billion, a PE ratio of 53.09, a price-to-earnings-growth ratio of 1.14 and a beta of 0.47. The firm has a fifty day simple moving average of $762.81 and a two-hundred day simple moving average of $766.75. The company has a current ratio of 1.28, a quick ratio of 1.00 and a debt-to-equity ratio of 1.86. Eli Lilly and Company has a 12 month low of $623.78 and a 12 month high of $935.63.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The company reported $6.31 earnings per share for the quarter, beating analysts' consensus estimates of $5.59 by $0.72. The firm had revenue of $15.56 billion for the quarter, compared to analyst estimates of $14.40 billion. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The business's quarterly revenue was up 37.6% compared to the same quarter last year. During the same period last year, the firm earned $3.92 earnings per share. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. Analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.